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Tuberous Sclerosis Complex (TSC) is a rare autosomal-dominant disorder caused by
mutations in the TSC1 or TSC2 genes. Patients with TSC may suffer from a wide range
of clinical manifestations; however, the burden of TSC and its impact on healthcare
resources needed for its management remain unknown. Besides, the use of resources
might vary across countries depending on the country-specific clinical practice. The aim
of this paper is to describe the use of TSC-related resources and treatment patterns
within the TOSCA registry. A total of 2,214 patients with TSC from 31 countries were
enrolled and had a follow-up of up to 5 years. A search was conducted to identify
the variables containing both medical and non-medical resource use information within
TOSCA. This search was performed both at the level of the core project as well as
at the level of the research projects on epilepsy, subependymal giant cell astrocytoma
(SEGA), lymphangioleiomyomatosis (LAM), and renal angiomyolipoma (rAML) taking into
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account the timepoints of the study, age groups, and countries. Data from the quality
of life (QoL) research project were analyzed by type of visit and age at enrollment.
Treatments varied greatly depending on the clinical manifestation, timepoint in the study,
and age groups. GAB Aergics were the most prescribed drugs for epilepsy, and mTOR
inhibitors are dramatically replacing surgery in patients with SEGA, despite current
recommendations proposing both treatment options. mTOR inhibitors are also becoming
common treatments in rAML and LAM patients. Forty-two out of the 143 patients (29.4%)
who participated in the QoL research project reported inpatient stays over the last year.
Data from non-medical resource use showed the critical impact of TSC on job status
and capacity. Disability allowances were more common in children than adults (51.1%
vs 38.2%). Psychological counseling, social services and social worker services were
needed by <15% of the patients, regardless of age. The long-term nature, together
with the variability in its clinical manifestations, makes TSC a complex and resource-
demanding disease. The present study shows a comprehensive picture of the resource
use implications of TSC.
Keywords: TSC, resource use, TOSCA, management, registry, rare diseases
INTRODUCTION
Tuberoussclerosis complex (TSC) is an autosomal-dominant
disorder characterized by the formation of hamartomatous
lesions in multiple organ systems (1) and the association with
a wide range of TSC-associated neuropsychiatric disorders,
abbreviated as TAND (2).
TSC is caused by mutations in either TSC1 or TSC2
genes. The proteins encoded by these two genes—
hamartin and tuberin—form a complex that inhibits
the mammalian target of rapamycin (mTOR) complex
1, which is involved in the regulation of cell growth and
proliferation (1).
The manifestations and the severity of the disease are variable,
even between relatives, and depend on size, number, location
and distribution of the lesions (3, 4). Common locations include
the brain, kidneys, lungs, skin, heart, and eyes (4–8). However,
TABLE 1 | Use of treatments according to follow-up visit.
Baseline
(N = 2211)
FU1
(N = 2099)
FU2
(N = 1935)
FU3
(N = 1664)
FU4
(N = 764)
FU5
(N = 147)
Patients with IS 721 151 120 91 45 14
Patients treated for IS (n, %) 698 (96.8) 145 (96.0) 113 (94.2) 85 (93.4) 44 (97.8) 14 (100.0)
Patients with FS 1,261 614 544 506 236 29
Patients treated for FS (n, %) 1,237 (98.1) 599 (97.6) 530 (97.4) 493 (97.4) 231 (97.9) 28 (96.6)
Patients with SEGA 553 489 468 420 208 52
Patients treated for SEGA (n, %) 221 (40.0) 187 (38.2) 188 (40.2) 181 (43.1) 101 (48.6) 22 (42.3)
Patients with rAML 1,062 1,067 1,041 945 472 121
Patients treated for rAML (n, %) 315 (29.7) 300 (28.1) 321 (30.8) 288 (30.5) 165 (35.0) 53 (43.8)
Patients with LAM 154 157 162 149 68 21
Patients treated for LAM (n, %) 50
(32.5)
47
(29.9)
54
(33.3)
43
(28.9)
20
(29.4)
0
(0.0)
no single symptom is observed in all patients, and none of the
symptoms can be considered as absolutely pathognomonic (6).
The use of resources and the costs of managing patients
with TSC have been estimated in several studies carried
out in Sweden (9), the United Kingdom (UK) (10–12),
the Netherlands (13), the United States (US) (14, 15), and
Canada (16). All of them have been developed on a national-
basis in European countries or in North America, and most
of them have been carried out in a limited number of
patients filtered by age or by clinical manifestation. Therefore,
the information coming from these studies is specific and
cannot be completely extrapolated to other countries or
clinical contexts. High variations across countries can appear
depending on the country-specific clinical practice. As a
consequence, the burden of TSC and its impact on the
use of healthcare resources required for its management
remain unknown.
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The TuberOus SClerosis registry to increase disease
Awareness (TOSCA) was a large scale non-interventional
study in patients with TSC, started in 2012 and was conducted
at 170 sites in 31 countries. TOSCA registry was totally founded
by Novartis AG and its related clinical study protocol and
final study results are disclosed on the ENCePP portal at
http://www.encepp.eu/ (EU PAS Register Number EUPAS324)
(17). The design and methodology of TOSCA were published
previously (8). In short, patients of any age with TSC were
enrolled and followed-up for up to 5 years. Patient data including
demographics and information related to clinical features of TSC
across all organ systems, comorbidities, and rare manifestations,
were collected at baseline and at regular visits scheduled at a
maximum interval of 1 year.
The registry consisted of a “core” part and six associated
research projects focusing on: epilepsy, subependymal
giant cell astrocytomas (SEGA), renal angiomyolipoma
(rAML)/lymphangioleiomyomatosis (LAM), genetics, quality
of life (QoL), and TSC-associated neuropsychiatric disorders
(TAND); the “core” part collected demographic data, family
history, prenatal history, disease features, and information on
treatments, whereas the research projects recorded in-depth data
related to specific disease manifestations or to specific aspects
of the disease (8). One of the research projects (research project
on QoL) recorded data on the use of medical and non-medical
resources for seven European countries (Belgium, Germany,
Italy, Spain, Sweden, France, and the UK).
Due to its long-term follow-up (up to 5 years) and to the
inclusion of patients of any age from different countries from all
over the world, the TOSCA registry offered a unique opportunity
to observe how treatment patterns for the manifestations of
TSC changed over time, and to evaluate differences in disease
management depending on the age of the patients or their
country of residence. In addition, results can be analyzed in
context with the results from the other research projects.
The aims of the present study were to analyse how the
treatment modalities in patients with TSC included in the
TOSCA registry changed during the 5 years of follow-up, to
identify differences in management as well as the availability
of medical and non-medical health resources with respect to
patients’ age or country of residence.
METHODS
This study was based on data obtained from the TOSCA registry.
The TOSCA registry was a non-interventional clinical study
founded by Novartis AG, designed and conducted according to
the Guidelines for Good Clinical Practice and ethical principles
FIGURE 1 | Treatments for Infantile Spasms in each Follow-up Visit. Patients may receive more than one treatment. Baseline data refers to patients who “ever had”
the manifestation. Other include lamotrigine, topiramate, levetiracetam and valproate.
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outlined in the Declaration of Helsinki (18, 19). After appropriate
approval by central and local research ethics committees, written
informed consent was obtained from all patients, parents, or
guardians, prior to enrollment.
The first step for the present manuscript was a search for
variables that could be of interest for the purpose of a study on
the use of TSC-related resources (including medical and non-
medical resources), and an exhaustive analysis of all the listings
and tables produced as part of the final analysis of the TOSCA
registry, in order to identify relevant outcomes and analyses for
each variable. The variables and potential analyses are detailed in
the Tables S1, S2.
Data on use of treatments (proportion of treated patients and
types of treatment) were available for the overall population of
patients included in the core registry. Data on the use of other
medical resources (hospitalizations, primary, and secondary care
visits) and on the use of non-medical resources (variables related
to education needs, patient or caregiver employment situation
and patient support/social services needs) were available for a
subset of 143 patients included in theQoL research project, which
was carried out in 7 European countries (Belgium, Germany,
Italy, Spain, Sweden, France, and the UK).
Treatment patterns were analyzed using the core registry data
according to 4 clinical manifestations (epilepsy, SEGA, LAM,
and rAML), the number of visits [baseline or follow-ups (FU1
to FU5), where FUs were conducted at intervals not longer than
12 months apart], the age group (≤2, >2 to ≤5, >5 to ≤9, >9 to
≤14, >14 to <18, ≥18 to ≤40, and >40 years), and the country
of residence (for those countries included in the QoL research
project; i.e., Belgium, Germany, Italy, Spain, Sweden, France, and
the UK). Baseline data were retrospectively collected and FU data
were prospectively collected up to 5 years. All the results were
reported in terms of absolute and relative frequencies.
The use of other medical resources and the use of non-medical
resources was analyzed for the overall population included in the
QoL research project. Again, all the results were reported in terms
of absolute and relative frequencies.
RESULTS
Baseline Characteristics of Patients
The baseline characteristics of patients enrolled in TOSCA
registry were analyzed in detail. In brief, a total of 2,214 patients
from 31 countries worldwide were enrolled into the study. Data
from 2,211 eligible patients were analyzed as part of the TOSCA
clinical study report delivered to Health Authorities by Novartis
AG. Data of 3 patients were excluded from the analysis because
of major protocol deviations. Of the analyzed patients, 1,152
FIGURE 2 | Treatments for Focal Seizures in each Follow-up Visit. Patients may receive more than one treatment. Baseline data refers to patients who “ever had” the
manifestation.
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(52.1%) were female. The median age at enrolment was 13 years
(range <1–71), and the median age at first TSC diagnosis was 1
year (range <1–69 years). The most common manifestation was
epilepsy occurring in 1,879 (85.0%) of patients. Among patients
with epilepsy, 1,343 (71.5%) had focal seizures (FS) and 735
(39.1%) had infantile spasms (IS). Other commonmanifestations
were hypomelanotic macules in 1,555 patients (70.3%), facial
angiofribromas in 1,533 patients (69.3%), and rAML in 1,317
patients (59.6%).
Another important manifestation was TAND, even though
it was the most underassessed aspect of TSC in the registry.
TAND assessment includes the evaluation of common behavioral
problems, psychiatric disorders, intellectual abilities, academic
performance, and neuropsychological difficulties. At baseline,
only 818 out of 2,211 (37%) patients reported to have at least
one behavioral problem, in 319 (14.4%) patients autism spectrum
disorder (ASD) and in 267 (12.1%) patients attention deficit
hyperactivity disorders (ADHD) was diagnosed, and 82 (3.7%)
and 132 (6.0%) patients had depressive disorders or anxiety,
respectively. In addition, 736 patients (33.3%) were reported
to have difficulties in academic performance. Among the 894
patients with reported TAND, normal intellectual ability (defined
as full scale IQ≥80) was reported for 44.2% (395/894).
Treatments
In the TOSCA registry, the proportion of patients who received
treatment varied largely depending on the clinical manifestations
(Table 1), with values at baseline (patients who ever had the
manifestation) ranging between 96.8% (698/721) for IS and
32.5% (50/154) for LAM. Almost all patients with epilepsy
received antiepileptic drug treatment without relevant variations
throughout the study (Table 1). At baseline, the most common
treatments were GABAergic agents (e.g., vigabatrin), both in
mono- and combination therapy), which were used in 79.3% of
treated patients with IS, and in 66.2% of treated patients with
FS (Figures 1, 2).
However, the use of GABAergic agents decreased over time,
reaching a minimum of 14.3% in the fifth FU visit for the IS
patients and 46.4% for FS patients. Other treatment options
such as mammalian target of rapamycin (mTOR) inhibitors, the
ketogenic diet (KD) and epilepsy surgery were used in <20%
FIGURE 3 | Treatments for Infantile Spasms by Country. Patients may receive more than one treatment.
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FIGURE 4 | Treatments for Focal Seizures by Country. Patients may receive more than one treatment.
of the patients at baseline, and remained relatively stable over
time (Figures 1, 2).
When analyzing the types of treatment by country,
GABAergics alone or in combination were by far the most
common treatment options in all countries both in patients
with IS (ranging between 46.7% in the UK and 96.2% in Spain)
and in patients with FS (ranging between 50% in the UK and
100% in Sweden) (Figures 3, 4). Adrenocorticotropic Hormone
(ACTH) was the second most common treatment for treating IS
in all countries except in Belgium. Other common treatments
for treating FS were epilepsy surgery (in Belgium, Italy, and
Spain) and mTOR inhibitors (in Sweden, Germany, and France)
(Figure 4). Of note, both surgery and mTOR inhibitors were
not used at all in patients with IS or FS from the UK, and in
patients with IS from Sweden. More than 50% of the treatments
in patients with FS were not specified (included in “others”
category) in all countries, even more than 90% in Italy and
Sweden (Figure 4).
At baseline, 40.0% of patients had ever received treatment for
SEGA and this proportion remained stable over time (Table 1).
mTOR inhibitors and surgery were themost common procedures
in patients with SEGA with marked differences depending
on follow-up, age and the country of residence (Figure 5).
At baseline, mTOR inhibitors were administered in 48.1% of
the patients who received treatment for SEGA, but their use
increased over time (reaching 86.4% of patients in the 1st FU visit
and 100% in the 5th). In contrast, 59.3% patients received surgery
at baseline, but the proportion of patients undergoing surgery
decreased over time as the use of mTOR inhibitors increased
(reaching 11.9% of patients in the 1st FU visit and no patients
in the 5th) (Figure 5).
The proportion of patients treated for SEGA also varied
depending on the age at baseline. Children aged 9–14 were
treated most commonly [50 (51.0%) patients received treatment]
while children aged <2 years and adults aged more than 40 years
were treated least frequently [7 (15.2%) and 8 (29.6%) of patients,
respectively]. Likewise, the types of treatment varied across
age groups. While mTOR inhibitors were the most common
treatments used in children aged 9 or less [reaching a peak (70%)
in those aged between 5 and 9], surgery was the most common
treatment in adolescents and adults [reaching a peak (87.5%) in
those aged more than 40] (Figure 6).
Regarding the use of treatments for SEGA by country, mTOR
inhibitors were more often prescribed in Germany (70% of the
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FIGURE 5 | Treatments for SEGA in each Follow-up Visit. Patients may receive more than one treatment. Baseline data refers to patients who “ever had” the
manifestation.
patients) and Spain (100% of the patients) than in the rest
of the participating countries (Figure 7). In contrast, surgery
was the most common treatment in Belgium (77.8%) and in
France (76.9%). The only patient from the UK (100%) also
underwent surgery.
With respect to rAML, the number of patients treated was
315 (29.7%) at baseline, kept at around 30% up to FU 3
and increased in FU 4 (35.0%) and FU 5 (43.8%) (Table 1).
Similarly to SEGA, mTOR inhibitors and embolization were
the most common treatments for rAML patients (Figure 8). At
baseline, 144 (45.7%) patients received mTOR inhibitors and
141 (44.8%) patients underwent embolization; however, the use
of all treatments consistently decreased with time with only 8
(15.1%) patients in FU 5 receiving mTOR inhibitors. Data on
embolizations were not available for any patient at the end of
the period and only one patient (0.6%) underwent this procedure
in FU 4 (Figure 8). rAML is an uncommon manifestation in
children. Therefore, most of the patients receiving treatment
for rAML were adolescent and adults (Figure 9). Embolizations
were rare in children (only 7.4% of patients aged 9–14 had
undergone this procedure) whereas more than half of rAML
patients aged 18–40 (51.8%) and older (58.3%) underwent this
procedure. In contrast, there was a high use of mTOR inhibitors
for rAML in these young patients, which certainly was prescribed
for other TSC manifestations, which decreased for older patients
(Figure 9). The distribution of treatments by country is shown
in Figure 10. It can be observed that mTOR inhibitors were
the most commonly used treatment option for rAML in all
countries (Figure 10).
As for LAM, the number of treated patients generally
decreased with time (Table 1). Again, mTOR inhibitors were
the most common treatment for this condition (60.0% of LAM
patients received mTOR inhibitors at baseline) and its use
increased up to 86.0% in FU 3 and 75.0% in FU4 (Figure 11).
Since, as expected, LAM was only diagnosed in patients aged ≥9
years, no data were available for younger patients. Adolescents
were treated with both chest surgery and mTOR inhibitors,
while most patients treated during adulthood received mTOR
inhibitors (Figure 12).
mTOR inhibitors were used for LAM treatment in all patients
in France and in Italy, in 66.7% in Germany, 50% in Belgium,
and in 25.0% in the UK. No data on the type of treatments
used in patients with LAM were available for Spain and
Sweden (Figure 13).
Hospitalizations and Visits
The frequency of hospitalizations was analyzed in the subset of
patients of the TOSCA registry included in the QoL research
project (N = 143). Regarding visits to the specialist, the same
subset was analyzed. Subjects from Spain (N = 11) were
excluded from the analysis because of data inconsistencies in
these patients. As a result, healthcare visits were analyzed in 132
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FIGURE 6 | Treatments for SEGA according to Age at Baseline. Patients may receive more than one treatment.
patients. A total of 88 visits to the specialists were reported over
12 months during the last year. Half of the patients (69/132;
52.3%) visited the specialist due to TSC at least once during the
last year, and a quarter (29/132; 22.0%) had 3 ormore visits. Visits
to the specialist for reasons other than TSC were reported for 34
patients (25.8%), and 14 of them (10.6%) reported 3 ormore visits
during the last year (Table S3). Visits to the general practitioner
(GP) were discarded from the analysis because of missing data
(information was missing or unknown for more than 50% of
the patients).
No hospitalizations were reported for 70.6% of the patients
over 12 months during the last year. A third of the patients
(41/143; 28.7%) reported at least one hospitalization, and 6.3%
(9/143) reported 3 or more hospitalizations (Table S4).
Information on the use of non-medical resources (education,
employment, use of social services and patient support
requirements) was collected within the QoL research project, and
this is summarized in Table S5.
Regarding education, 28 children (31.8%) were not
in a mainstream school, and the rest (N = 57; 64.8%)
were educated in a mainstream school. Of those who
attended a mainstream school, 64.9% received special
education within the school, and for 45.6% (26/57)
the school offered special programs adequate to their
condition (Table S5).
In the questionnaire used for data collection into this research
project, 55 adults with TSC who were able to complete the
questionnaire themselves and 88 carers for children with TSC
reported their work experience. Only half of the individuals
[41.8% (23/55) adult patients and 65.9% (58/88) children’s carers]
reported to have a job. A quarter of the adult patients (14/55;
25.5%) reported that they were not able to work due to TSC and
half (28/55; 50.9%) stated that TSC had an impact on their career.
The corresponding figures for these two items in children’s carers
were 9.1% (8/88) and 56.8% (50/88) (Table S5).
Besides, half of the children (45/88; 51.1%) and 38.2%
(21/55) of the adults received a disability allowance, and 20%
(11/55) of the adults received support with daily activities. Other
services such as psychological counseling, social services, and
social worker services were received by <15% of the patients
irrespective of their age (Table S5).
DISCUSSION
The present work investigated treatment patterns and use of
medical/non-medical resources in patients enrolled into the
TOSCA registry. Compared to other studies carried out in
single countries including a limited number of patients of
certain age-groups or with specific manifestations (9–16, 20),
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FIGURE 7 | Treatments for SEGA by Country. Patients may receive more than one treatment.
the TOSCA registry represented a unique opportunity to analyse
the treatment patterns and use of resources in a large cohort
of pediatric and adult patients with a wide range of clinical
manifestations who had been diagnosed and treated in different
countries over a 5-year observation period. This strengthens
the external validity of the results and provides clues on how
treatment patterns have changed over time and across regions.
One of the purposes of the 2012 International TSC Consensus
Conference was to provide recommendations for standardized
diagnostic criteria, management and surveillance of TSC
regardless of age (21). This study shows that treatment patterns
mostly depend on the clinical manifestations of the disease but
also that they depend on the age and the country of residence
of the patients. For instance, there are important variations in
the use of mTOR inhibitors in patients with SEGA throughout
countries (ranging from none in the UK to 100% in Spain), and
on the age of the patients (ranging from 70% in patients aged 5–9
to 0% in patients aged >40).
The differences between countries reflect not only the effect
of clinical practice, but also the effect of access barriers due to
different time points at which mTOR inhibitors were available
for the various indications in specific countries and/or healthcare
systems. For instance, everolimus was reimbursed for patients
with FS in January 2017 in Germany and April 2018 in Sweden,
but was not made available until late 2018 or the beginning of
2019 in the rest of European countries (June 2018 in Spain,
September 2018 in Italy, December 2018 in Belgium, and in
the UK, and January 2019 in France). For patients with SEGA,
everolimus was reimbursed in October 2011 in Germany and
in the UK only through the Individual Funding Request (IFR)
route, while it was not available until 2016 in Italy and in
Belgium. Another example is the availability of mTOR inhibitors
for patients with rAML as everolimus was reimbursed in the UK
in October 2011, in Germany in November 2012, and in France
in April 2014, even though it was not available in Spain until
April 2015 and in Belgium until August 2016, and it is still not
yet reimbursed in Italy.
In addition, the differences in age groups might reflect
differences in clinical practice between pediatric and adult
neurologists in those manifestations treated before the TOSCA
registry and within the time horizon of the TOSCA registry
(i.e., after baseline). In line with the current guidelines (21,
22), which recommend the use of vigabatrin as a first-line
antiepileptic drug treatment in patients with TSC and either
IS or FS before the age of 1 year, the most prescribed drugs
were GABAergics. In any case, these results must be interpreted
with caution due to the large proportion of treatments included
in the category “others” (at baseline, 44.4% for IS and 66.5%
for FS) and to the fact that the category “GABAergics”
included a large number of different AEDs. In future studies,
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FIGURE 8 | rAML Treatments according to Follow-Up. Patients may receive more than one treatment. Baseline data refers to patients who “ever had” the
manifestation.
more attention should therefore be paid to the definition of
treatment variables.
Besides, one has to take into consideration, that TOSCA
enrollment started in August 2012, and last data entry was in
August 2017. Everolimus, was approved by European Medicines
Agency (EMA) for the treatment of drug-resistant epilepsy
as late as in January 2017. It was therefore not possible to
evaluate the consequences of the approval of this mTOR inhibitor
on the treatment patterns of patients with TSC-associated
epilepsies. Despite this, physicians struggling to treat TSC-
associated seizures that had proved refractory to conventional
AED treatment had already started using everolimus with
increasing frequency. We hypothesize that this use was due to
other TSC-associated conditions and on-going mTOR studies
in epilepsy.
This study shows how mTOR inhibitors have become
common treatments for a variety of manifestations in patients
with TSC such as SEGA, LAM, and rAML. However, since more
than one manifestation might co-occur in a single patient, it
may not be correct to attribute the use of mTOR inhibitors
to a single manifestation. An example of this is the use of
mTOR inhibitors in patients with LAM as a consequence of the
growing use of mTOR inhibitors for other indications in patients
with TSC.
In patients with SEGA, current recommendations propose
the use of surgical resection for acutely symptomatic SEGA,
the use of both surgery and mTOR inhibitors for growing but
asymptomatic SEGA and the use of mTOR inhibitors for patients
with large or bilateral SEGA that are not amenable to surgical
resection (21, 23). In line with the recommendations, the analyses
on the use of treatment according to FU visits, countries, and
age groups in the patients included in the TOSCA registry show
that the increases in the use of mTOR are often accompanied by
decreases in the use of surgery. For instance, it is particularly
striking to observe how the increasing use of mTOR inhibitors
registered in the different FU visits (Figure 5) is almost a mirror
image of the decreasing use of surgery, and to observe how in age
groups and countries where mTOR inhibitors are used the most,
surgery is used the least and vice versa (Figures 6, 7).
The exact economic cost of these changes was not possible to
evaluate from this dataset. However, the potential reductions and
delays in the use of surgery may have economic implications not
only at the time of treatment initiation, but also in the follow-
up of the patients. In this regard, a study comparing pre-surgery
and post-surgery costs in TSC patients with SEGA surgery carried
out in the US (24) found that medication and total costs in the
post-surgery year were 1.6–4.3 times the costs in the pre-surgery
year. Unfortunately, no formal economic evaluations comparing
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FIGURE 9 | rAML Treatments according to Age at Baseline. Patients may receive more than one treatment.
surgery and mTOR inhibitors in patients with SEGA have been
carried out.
Interestingly, the use of surgery in patients with SEGA was
lower in the TOSCA registry (Figure 5) than in a previous survey
study carried out by Rentz et al. (15). This study included 676
patients -or caregivers- and reported surgery in 31 and 47%
of pediatric and adult patients, respectively, but did not report
any use of mTOR inhibitors in any of the groups. Comparing
the use of medical resources, and in particular the use of
surgery depending on whether the patients receive treatment
with mTOR inhibitors is an area of major interest that remains
largely unexplored.
The results observed in rAML and LAM are in line with
those observed in patients with SEGA. However, as stated
above, since we are considering a population with co-occurring
manifestations it is difficult to determine if mTOR inhibitors
were used to treat these particular manifestations. It is worth
commenting that in Sweden, where 100% of patients with rAML
who received treatment received mTOR inhibitors, no patients
had nephrectomy surgery; by contrast, in Italy, where only 12.5%
of the patients who received treatment for this manifestation
were treated with mTOR inhibitors, 62.5% had nephrectomy
surgery (Figure 10).
While these results might also be influenced by the age of the
patients in each country at baseline, it is important to emphasize
that embolization surgery in rAML and chest surgery in LAM are
rescue therapies in urgent situations, but mTOR inhibitors are
the only available treatment that both modifies the disease and
improves the outcomes (21, 25, 26).
A reason for the increased use of mTOR inhibitors in patients
with LAM might be its inclusion in the recent international
guidelines published for the diagnosis and management of LAM,
in which mTOR inhibitors were recommended for patients with
abnormal or declining lung function or with problematic chylous
effusions, that could have affected the treatment patterns (27).
Given that TSC is a multi-organ disease, treatment of a certain
manifestation with a systemic mTOR inhibitor will probably
result in reductions of the use of surgical interventions for other
manifestations as well. Concomitant systemic effects in patients
treated with mTOR inhibitors have been reported (28). The
impact of these effects on the use of other treatments or other
medical resources have not yet been analyzed and is an interesting
topic for future research. The consistent reductions in the use of
surgery observed for all the manifestations in the present study
support this hypothesis.
Similar to other studies (11, 15, 20), this study shows that
patients with TSC are demanding healthcare resource users, but
it also shows that the use of resources is not evenly distributed
across patients and countries. In this regard, while a third of
the patients included in the QoL research project did not attend
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FIGURE 10 | rAML Treatment by Country. Patients may receive more than one treatment.
any specialist due to TSC during the past year, a quarter of the
patients had three or more visits in the same period. Likewise,
while 71% of the patients were not hospitalized at any time, up to
6.3% were hospitalized three or more times during the past year.
In future studies, it would be interesting to identify the clinical
features of the patients who are likely to be more intense resource
users in order to provide a better allocation of resources for the
management of the disease.
The present study also shows that the impact of TSC on
education and on employability is high. More than half of
the children had special needs (were not in a mainstream
school or received special education within their school), and
unemployment rates were high both in patients and caregivers
of children with TSC (34.1% in children’s caregivers, and up to
50% in adults with TSC). Therefore, the economic impact of a
TSC diagnosis is high for the patients and for their families. In
line with these results, a multicenter French study that included
adult patients with TSC and with a diagnosed epilepsy before 16
years old found that 52% of patients required special education
programs and only 37% reported having a stable professional
life, even though 65% of them had a salary below the minimum
income threshold in France (29).
The rate of patients receiving psychological support was
reportedly low both for adults and children. The same low rates
were observed in the multicenter French study, where 35% of
children and 13% of adults had a regular psychological follow-
up (29). This contrasts with the expected rates of TAND and
suggests that the psychological needs of patients are not being
addressed properly. Of note, physicians’ unawareness and no
clear guidelines on TAND evaluation before 2013 might have
led to more missing data, underestimating TAND difficulties.
However, a set of consensus guidelines for the evaluation of
neuropsychiatric problems had already been published in 2005
(30), suggesting that there was a lack of implementation of
existing guidelines. Likewise, the proportion of patients receiving
disability allowances was higher in children (51.1%) than adults
(38.2%), the use of social worker services was reportedly lower
in both children and adults (8.0% in children and 1.8 % in
adults), and <10% of patients (5.7% of children and 3.6% of
adults) reported to have received help while completing benefit
applications. Altogether, these results indicate that many patients
with TSC might be unaware of the possibility of receiving
social services or that these services are not available in all
the countries.
A strength of the TOSCA registry was the prospective follow-
up of patients, which allowed to trace changes in treatment
patterns over time. However, data from the two last follow-up
visits (after 4 and 5 years) were available, for only 764 and 147
patients out of 2,211, respectively. Hence, caution is required
when drawing conclusions from the last two visits. Although
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FIGURE 11 | LAM Treatments according to Follow-Up. Patients may receive more than one treatment. Baseline data refers to patients who “ever had” the
manifestation.
the number of patients in the last follow-up is relatively low
compared to the patients for whom data was available at baseline,
other studies on use of resources in patients with TSC have been
carried out in patient cohorts with a smaller sample size. For
instance, a study carried out by Skalicky et al. (20) included 116
patients and another study carried out by Lennert et al. (12)
included only 95 patients.
The present study has some limitations. The main caveat was
that data relating resource use from the QoL research project was
collected for <10% of the patients included in the registry, which
is in contrast with excellent data quality for the medical aspects
of TSC recorded in the core study. This might be due to the
fact that data collection of data into the QoL research study was
not mandatory, due to the observative nature of the registry, or
might be due to the absence of site monitoring review of the QoL
research project data collection. Carrying out specific studies to
broaden the evidence on the use of medical resources in patients
with TSC remains an interesting topic for future research.
Also, the observational nature of the TOSCA registry meant
that only available data from standard clinical practice was
supposed to collected. As recruitment was made through
centers with expertise in TSC, where mainly moderate-severe
TSC manifestations are seen, milder cases could have been
underestimated. Getting data from routine practice also meant
discrepancies in some variables, as the way information is
collected within centers is not homogeneous. In any case,
the involvement of various centers and specialists has helped
inclusion of a significant number of TSC patients, which should
be representative of real clinical practice.
Unlike in other studies evaluating the costs of managing TSC
manifestations carried out in a single country (10, 11, 13, 14, 16),
costs estimations could not be performed given that the analyses
were conducted using data from 31 countries with different
healthcare systems.
Furthermore, there are differences between the design of this
study and that of previous studies evaluating the use of resources
in TSC patients (10–16, 20), which limits the conclusions that
can be drawnwhen comparing our results. Besides the differences
in geographical areas and timeframes, while the TOSCA registry
included patients with proven TSC, but regardless of specific
manifestations, only three of the studies published so far (11,
14, 15) were carried out in an overall TSC population (i.e., not
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FIGURE 12 | LAM Treatments according to Age at Baseline. Patients may receive more than one treatment.
defined by a specific manifestation), while the rest included only
patients with epilepsy (10, 12), SEGA (20), LAM (16), or kidney
involvement (13).
Our results show that the use of treatments for specific
conditions greatly differed depending on the clinical
manifestations and the specialists caring for the patients,
the period analyzed, as well as their ages and the countries
of residence. Therefore, comparing the results of the patients
included in the TOSCA registry with those observed in other
studies without paying attention to their baseline characteristics
might be methodologically inappropriate.
Information about healthcare visits and hospitalizations, as
well as about use of non-medical resources, was only available for
a cohort of 143 patients from the 7 European countries included
in the QoL research project. The fact that all the patients included
in this project were treated in European countries limits the
ability to extrapolate the conclusions to other continents. Also,
some data inconsistencies were found regarding specialist visits
in Spanish patients and the information regarding primary care
(GP visits) was missing or unknown for half of the patients
(50.3% for TSC-related visits and 53.9% for visits for other
reasons). Future studies should incorporatemonitoring strategies
during data collection in order to minimize these issues.
Comparing the use of medical resources in patients with
TSC treated with or without mTOR inhibitors remains
another area of interest for future research. In addition, the
information on medical and non-medical resources in the
QoL research project was provided by the patient itself or
a caregiver. Although this has been a common methodology
in similar studies (10, 11, 15), there can be inconsistencies
or missing data if patients do not remember the answers or
do not understand the questions. Future research should pay
attention to this point, involving specific staff to supervise
data completion.
In conclusion, in spite of the limitations indicated above, this
study has provided more detailed information about treatment
patterns and current use of medical and non-medical resources
in a large cohort of patients with TSC followed for a long
period of time in seven European countries. It shows how mTOR
inhibitors have become common treatments for certain TSC-
related manifestations, often accompanied by reductions in the
use of surgery. In addition, it confirms that the use of medical
Frontiers in Neurology | www.frontiersin.org 14 October 2019 | Volume 10 | Article 1144
Marques et al. Use of Resources in TOSCA
FIGURE 13 | LAM Treatments by Country. Patients may receive more than one treatment.
and non-medical resources in patients with TSC is high. Further
research is needed to determine the impact of mTOR inhibitors
on the use of other resources, and in particular, to quantify the
economic consequences of potential reductions in the use of
other treatments, primarily surgery.
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kliniskās universitātes slimnicas, Attistibas biedribas Kliniskās
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